[{"data":1,"prerenderedAt":178},["ShallowReactive",2],{"drug-nebivolol":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":21,"regimens":60,"contraindications":83,"warnings":93,"renal":94,"monitoring":95,"interactions":96,"review":97,"examples":100,"atc":106,"iran":108,"links":120,"populations":137,"usApproval":173},"nebivolol",1,{"fa":7,"en":8},"نبیولول","Nebivolol","cardiovascular",{"fa":11,"en":12},"بتابلاکر انتخابی β1 با اثر گشادکنندگی عروق","β1-selective beta-blocker with vasodilating action",[14],{"name":15,"market":16},"Bystolic","US",[18,19,7,20],"bystolic","nebilet","نبیلت",[22,36,44,52],{"id":23,"form":24,"route":25,"label":26,"concentration":27,"markets":31,"refs":32},"tab-2-5","tablet","oral","2.5 mg tablet",{"amount":28,"unit":29,"perUnit":24,"scored":30},2.5,"mg",false,[16],[33],{"source":34,"section":35},"fda-nebivolol","3",{"id":37,"form":24,"route":25,"label":38,"concentration":39,"markets":41,"refs":42},"tab-5","5 mg tablet",{"amount":40,"unit":29,"perUnit":24,"scored":30},5,[16],[43],{"source":34,"section":35},{"id":45,"form":24,"route":25,"label":46,"concentration":47,"markets":49,"refs":50},"tab-10","10 mg tablet",{"amount":48,"unit":29,"perUnit":24,"scored":30},10,[16],[51],{"source":34,"section":35},{"id":53,"form":24,"route":25,"label":54,"concentration":55,"markets":57,"refs":58},"tab-20","20 mg tablet",{"amount":56,"unit":29,"perUnit":24,"scored":30},20,[16],[59],{"source":34,"section":35},[61],{"id":62,"disease":63,"label":64,"population":67,"type":71,"unit":29,"dose":72,"refs":73,"notes":76},"htn","hypertension",{"fa":65,"en":66},"فشار خون — شروع ۵ mg یک بار در روز (تا ۴۰ mg)","Hypertension — start 5 mg once daily (up to 40 mg)",{"minAge":68},{"value":69,"unit":70},18,"year","fixed",{"perDose":40,"dosesPerDay":5},[74],{"source":34,"section":75},"2.1",[77],{"text":78,"refs":81},{"fa":79,"en":80},"هر ۲ هفته در صورت نیاز تا ۴۰ mg. CrCl زیر ۳۰: شروع ۲٫۵ mg.","Increase at 2-week intervals as needed up to 40 mg. CrCl \u003C30: start 2.5 mg.",[82],{"source":34,"section":75},[84],{"id":85,"severity":86,"text":87,"refs":90},"ci","block",{"fa":88,"en":89},"برادی‌کاردی شدید؛ بلوک بالاتر از درجه ۱؛ شوک کاردیوژنیک؛ نارسایی قلب جبران‌نشده؛ سندرم سینوس بیمار بدون پیس‌میکر؛ نارسایی شدید کبد؛ حساسیت.","Severe bradycardia; heart block above first degree; cardiogenic shock; decompensated HF; sick sinus without pacemaker; severe hepatic impairment; hypersensitivity.",[91],{"source":34,"section":92},"4",[],[],[],[],{"status":98,"reviewer":99,"date":99},"unverified",null,[101],{"regimen":62,"formulation":37,"input":102,"expect":105},{"ageYears":103,"weightKg":104},50,80,{"perDose":40,"tabletsPerDoseRounded":5},[107],"C07AB12",{"status":109,"forms":110,"refs":115},"registered",[111],{"code":112,"en":113,"fa":114},"07165","NEBIVOLOL 5MG TAB","قرص نبیوولول ۵ میلی‌گرم",[116],{"source":117,"section":118,"url":119},"darooyab-generic","G-1788\u002FNebivolol","https:\u002F\u002Fwww.darooyab.ir\u002FG-1788\u002FNebivolol",[121,125,129,132,135],{"kind":122,"url":123,"label":124},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=212682","ANDA212682",{"kind":126,"url":127,"label":128},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=51d3f12f-94cc-4f58-94d3-61990e16adfc","FDA Nebivolol",{"kind":130,"url":131,"label":8},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa608029.html",{"kind":133,"url":134,"label":107},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=C07AB12",{"kind":136,"url":119,"label":8},"darooyab",{"pregnancy":138,"lactation":147,"pediatric":155,"geriatric":164},{"level":139,"text":140,"quote":143,"refs":144},"caution",{"fa":141,"en":142},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary Available data regarding use of nebivolol tablets in pregnant women are insufficient to determine whether there are drug-associated risks of adverse developmental outcomes.",[145],{"source":34,"section":146},"8.1",{"level":139,"text":148,"quote":151,"refs":152},{"fa":149,"en":150},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary There is no information regarding the presence of nebivolol in human milk, the effects on the breastfed infant, or the effects on milk production.",[153],{"source":34,"section":154},"8.2",{"level":156,"text":157,"quote":160,"refs":161},"not-established",{"fa":158,"en":159},"برچسب: ایمنی و اثربخشی در کودکان ثابت نشده است.","Label: safety and effectiveness in children have not been established.","Safety and effectiveness in pediatric patients have not been established.",[162],{"source":34,"section":163},"8.4",{"level":165,"text":166,"quote":169,"refs":170},"ok",{"fa":167,"en":168},"برچسب: در سالمندان تفاوت یا تنظیم دوز خاصی ذکر نشده.","Label: no specific difference or dose adjustment stated for older adults.","No overall differences in efficacy or in the incidence of adverse events were observed between older and younger patients.",[171],{"source":34,"section":172},"8.5",{"kind":174,"refs":175,"id":124},"ANDA",[176],{"source":34,"section":177},"SPL approval \u002F marketing category",1792111462317]